Skip to main content
. 2017 Jul 28;7(9):e00776. doi: 10.1002/brb3.776

Table 2.

Proportion of patients in MCI and subjective cognitive decline (SCD) with 0–4 pathologic biomarkers

aMCI (n = 53) naMCI (n = 26) SCD (n = 38)
0 26.4% 40.7% 41.2%
1 26.4% 33.3% 35.3%
2 18.9% 22.2% 20.6%
3 24.5% 3.7% 2.9%
4 3.8% 0% 0%

Percentage of clinical groups with 0–4 pathological biomarkers.